In a similar study with other SGLT2 inhibitors, the DECLARE-TIMI 58 trial (42), treatment with dapagliflozin significantly reduced by 17% the primary endpoint of heart failure plus cardiovascular death in patients with type 2 diabetes mellitus who had high risks for cardiovascular events, including those with existing cardiovascular diseases, although such cardioprotective effects were limited to the onset of heart failure. Here, SLC5A2 is linked to diabetes mellitus.